Jason M. Elinoff, Ulas Bagci, Brad Moriyama, Jennifer L

Slides:

Advertisements

Similar presentations

Survival in a Recent Cohort of Mechanically Ventilated Pediatric Allogeneic Hematopoietic Stem Cell Transplantation Recipients Josephus P.J. van Gestel,

Advertisements

Immune Reconstitution in Recipients of Photodepleted HLA-Identical Sibling Donor Stem Cell Transplantations: T Cell Subset Frequencies Predict Outcome

Ulas D. Bayraktar, Denái R. Milton, Elizabeth J

The Effect of Statin Use at the Time of Autologous Transplant on Response and Survival in Multiple Myeloma Mehdi Hamadani, Erinn Hade, Don M. Benson,

Incidence and Causes of Hospital Readmission in Pediatric Patients after Hematopoietic Cell Transplantation David Stephen Shulman, Wendy B. London, Dongjing.

Increased Levels of Tumor Necrosis Factor α Are Associated with an Increased Risk of Cytomegalovirus Infection after Allogeneic Hematopoietic Stem Cell.

The Outcome of Sibling and Unrelated Donor Allogeneic Stem Cell Transplantation in Adult Patients with Acute Myeloid Leukemia in First Remission Who Were.

Increased Risk of Cervical Dysplasia in Long-Term Survivors of Allogeneic Stem Cell Transplantation—Implications for Screening and HPV Vaccination Bipin.

Peter Hurley, Suma Konety, Qing Cao, Daniel Weisdorf, Anne Blaes

Survival in a Recent Cohort of Mechanically Ventilated Pediatric Allogeneic Hematopoietic Stem Cell Transplantation Recipients Josephus P.J. van Gestel,

Influence of Stem Cell Source on Outcomes of Allogeneic Reduced-Intensity Conditioning Therapy Transplants Using Haploidentical Related Donors Kenneth.

Fatal Hyperacute Graft-versus-Host Disease following Denileukin Diftitox Treatment for Recurrent T Cell Lymphoma after Allogeneic Stem Cell Transplantation

Allogeneic Stem Cell Transplantation in Myelofibrosis

Inhaled Cyclosporine Solution for the Treatment of Bronchiolitis Obliterans Following Hematopoietic Stem Cell Transplantation (HSCT) or Lung Transplantation

Salivary Gland Involvement in Chronic Graft-Versus-Host Disease: Prevalence, Clinical Significance, and Recommendations for Evaluation Matin M. Imanguli,

Outcome of Respiratory Syncytial Virus Lower Respiratory Tract Disease in Hematopoietic Cell Transplant Recipients Receiving Aerosolized Ribavirin: Significance.

Characterizing Donor-Derived Cells in Nonhematopoietic Tissue

Sabina Kersting, Leo F. Verdonck

Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic.

Assessment of the Hematopoietic Cell Transplantation Comorbidity Index in Non- Hodgkin Lymphoma Patients Receiving Reduced-Intensity Allogeneic Hematopoietic.

A Critical Care and Transplantation-Based Approach to Acute Respiratory Failure after Hematopoietic Stem Cell Transplantation in Children Lama Elbahlawan,

The Effect of Bone Marrow Plasma Cell Burden on Survival in Patients with Light Chain Amyloidosis Undergoing High-Dose Melphalan and Autologous Stem Cell.

Carbon Monoxide Diffusion Capacity: How Low Can You Go for Hematopoietic Cell Transplantation Eligibility? Jason W. Chien, Keith M. Sullivan Biology.

Betty T. Tran, Abigail Halperin, Jason W. Chien

Bronchiolitis Obliterans Syndrome (BOS), Bronchiolitis Obliterans Organizing Pneumonia (BOOP), and Other Late-Onset Noninfectious Pulmonary Complications.

Jane Kempenich, Kelly Buck, John Hermanson, Jason Dehn, MPH

Increased Risk of Bone Loss without Fracture Risk in Long-Term Survivors after Allogeneic Stem Cell Transplantation Bipin N. Savani, Theresa Donohue,

Symptom Distress Predicts Long-Term Health and Well-Being in Allogeneic Stem Cell Transplantation Survivors Margaret F. Bevans, Sandra A. Mitchell, John.

Efficacy and Safety of Ex Vivo Cultured Adult Human Mesenchymal Stem Cells (Prochymal™) in Pediatric Patients with Severe Refractory Acute Graft-Versus-Host.

Natural history of pulmonary complications in children after bone marrow transplantation Mark Eikenberry, Hana Bartakova, Todd Defor, Imad Y. Haddad,

Incidence Rate of Fluoroquinolone-Resistant Gram-Negative Rod Bacteremia among Allogeneic Hematopoietic Cell Transplantation Patients during an Era of.

High Rate of Long Term Complete Remission for Patients with Chronic Lymphocytic Leukemia (CLL) Who Relapse after Allogeneic Stem Cell Transplantation.

Recovery of Pulmonary Function after Allogeneic Hematopoietic Cell Transplantation in Children Predicts Improved Survival Ashok Srinivasan, William Mitchell,

Reduced-Intensity Allogeneic Stem Cell Transplantation in Children and Young Adults with Ultrahigh-Risk Pediatric Sarcomas Kristin Baird, Terry J. Fry,

Risk Factors and Outcome of Chronic Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation—Results from a Single-Center Observational Study

Biology of Blood and Marrow Transplantation

Follicular Lymphoma: Prognostic Factors, Conventional Therapies, and Hematopoietic Cell Transplantation Laurie H. Sehn, Timothy S. Fenske, Ginna G. Laport

Improvement of Pulmonary Function with Imatinib Mesylate in Bronchiolitis Obliterans Following Allogeneic Hematopoietic Cell Transplantation Navneet.

Correlation between the numbers of naive T cells infused with blood stem cell allografts and the counts of naive T cells after transplantation Jan Storek,

Long-Term Outcomes of Critically Ill Adult Allogeneic Hematopoietic Stem Cell Recipients Prakash Vishnu, Udit Roy, Pramod Guru, Colleen Thomas, Candido.

Pulmonary Cytolytic Thrombi after Allogeneic Hematopoietic Cell Transplantation: A Further Histologic Description Antoinette Peters, J. Carlos Manivel,

Favorable Overall Survival with Fully Myeloablative Allogeneic Stem Cell Transplantation for Follicular Lymphoma John Kuruvilla, Gregory Pond, Richard.

Incidence, Predisposing Factors, and Outcome of Engraftment Syndrome in Pediatric Allogeneic Stem Cell Transplant Recipients Irene Schmid, Daniel Stachel,

Autologous Stem Cell Transplantation Is an Effective Salvage Therapy for Primary Refractory Multiple Myeloma Christopher Parrish, Amin Rahemtulla, Jim.

Pharmacokinetic Evaluation of the Drug Interaction between Intravenous Itraconazole and Intravenous Tacrolimus or Intravenous Cyclosporin A in Allogeneic.

Sabina Kersting, Ronald J. Hené, Hein A. Koomans, Leo F. Verdonck

Outcomes of Maintenance Therapy with Bortezomib after Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Dharshan Sivaraj, Michael.

Lung Function, Pulmonary Complications, and Mortality after Allogeneic Blood and Marrow Transplantation in Children Zühre Kaya, Daniel J. Weiner, Deniz.

Outcomes of Cord Blood Transplantation as Salvage Therapy after Graft Failure or Relapse after Prior Allogeneic Transplantation Rachel B. Salit, Filippo.

Repair of Impaired Pulmonary Function Is Possible in Very-Long-Term Allogeneic Stem Cell Transplantation Survivors Natasha A. Jain, Priyanka A. Pophali,

Equivalent Survival for Sibling and Unrelated Donor Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia John Moore, Ian Nivison-Smith,

What is quality in a transplant program?

Rituximab Administration within 6 Months of T Cell-Depleted Allogeneic SCT is Associated with Prolonged Life-Threatening Cytopenias Zachariah McIver,

Donor Cell Leukemia: A Review

Immune Reconstitution in Recipients of Photodepleted HLA-Identical Sibling Donor Stem Cell Transplantations: T Cell Subset Frequencies Predict Outcome

Favorable Outcomes in Patients with High Donor-Derived T Cell Count after In Vivo T Cell–Depleted Reduced-Intensity Allogeneic Stem Cell Transplantation

Systemic Toxoplasmosis Post Allogeneic Stem Cell Transplantation (Allo-SCT): Lessons Learned from HIV? Marie von Lilienfeld-Toal, MD, Maria Gilleece,

Cytomegalovirus (CMV) Infection and Disease Incidence and Risk Factors Across Diverse Hematopoietic Cell Transplantation (HCT) Platforms Using a Standardized.

Reticulocyte Maturation Parameters Are Reliable Early Predictors of Hematopoietic Engraftment after Allogeneic Stem Cell Transplantation J.R. Molina,

Extramedullary Relapse of Acute Myelogenous Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: Better Prognosis Than Systemic Relapse

Long-term Outcome of Hodgkin Disease Patients Following High-Dose Busulfan, Etoposide, Cyclophosphamide, and Autologous Stem Cell Transplantation—A Similar.

Mammen Chandy Biology of Blood and Marrow Transplantation

Allogeneic Hematopoietic Cell Transplantation Using Treosulfan-Based Conditioning for Treatment of Marrow Failure Disorders Lauri M. Burroughs, Akiko.

Reduced Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation: Current Perspectives Brenda M. Sandmaier, Stephen Mackinnon, Richard.

Prediction and prevention of transplant-related mortality from pulmonary causes after total body irradiation and allogeneic stem cell transplantation

Prospective Monitoring of Tumor Necrosis Factor α and Interferon γ to Predict the Onset of Acute and Chronic Graft-versus-Host Disease after Allogeneic.

Bronchiolitis Obliterans Syndrome (BOS), Bronchiolitis Obliterans Organizing Pneumonia (BOOP), and Other Late-Onset Noninfectious Pulmonary Complications.

Monocyte Recovery at Day 100 Is Associated with Improved Survival in Multiple Myeloma Patients Who Undergo Allogeneic Hematopoietic Cell Transplantation

Mary Eapen Biology of Blood and Marrow Transplantation

Induction Therapy with Bortezomib Followed by Bortezomib-High Dose Melphalan and Stem Cell Transplantation for Light Chain Amyloidosis: Results of a Prospective.

Presentation transcript:

Recombinant Human Factor VIIa for Alveolar Hemorrhage Following Allogeneic Stem Cell Transplantation Jason M. Elinoff, Ulas Bagci, Brad Moriyama, Jennifer L. Dreiling, Brent Foster, Nicole J. Gormley, Rachel B. Salit, Rongman Cai, Junfeng Sun, Andrea Beri, Debra J. Reda, Farhad Fakhrejahani, Minoo Battiwalla, Kristin Baird, Jennifer M. Cuellar-Rodriguez, Elizabeth M. Kang, Stephen Z. Pavletic, Dan H. Fowler, A. John Barrett, Jay N. Lozier, David E. Kleiner, Daniel J. Mollura, Richard W. Childs, Anthony F. Suffredini Biology of Blood and Marrow Transplantation Volume 20, Issue 7, Pages 969-978 (July 2014) DOI: 10.1016/j.bbmt.2014.03.015 Copyright © 2014 Terms and Conditions

Figure 1 Survival in the rFVIIa and conventional therapy groups. Shown are Kaplan-Meier survival curves depicting outcomes in the first 180 days after onset of the initial AH episode. The solid line represents the rFVIIa group; the dashed line, the conventional therapy group. Biology of Blood and Marrow Transplantation 2014 20, 969-978DOI: (10.1016/j.bbmt.2014.03.015) Copyright © 2014 Terms and Conditions

Figure 2 Extent of radiographic pulmonary pathology at the onset of AH. Shown are representative surface renderings of pulmonary parenchymal pathology at the onset of AH from 5 different patients in the rFVIIa group. (A) Patient 8; 8%. (B) Patient 21; 20%. (C) Patient 5; 25%. (D) Patient 13; 37%. (E) Patient 11; 47%. Total lung volume is outlined in blue, and pathological areas are highlighted in light green. Biology of Blood and Marrow Transplantation 2014 20, 969-978DOI: (10.1016/j.bbmt.2014.03.015) Copyright © 2014 Terms and Conditions

Figure 3 Effect of rFVIIa therapy on ICU length of stay (LOS), duration of mechanical ventilation (MV), resolution of AH, and duration of supplemental oxygen use in the rFVIIa and conventional therapy groups. There was no between-group difference in ICU length of stay due to AH (episodes included in analysis: rFVIIa, 23 of 43; conventional therapy, 8 of 14; P = .63), duration of mechanical ventilation due to AH (rFVIIa, 25 of 43; conventional therapy, 7 of 14; P = .89), time to resolution of AH (rFVIIa, 30 of 43; conventional therapy, 10 of 14; P = .50), or duration of supplemental oxygen use from the onset of the initial episode of AH (rFVIIa, 23 of 23; conventional therapy, 14 of 14; P = .55). Biology of Blood and Marrow Transplantation 2014 20, 969-978DOI: (10.1016/j.bbmt.2014.03.015) Copyright © 2014 Terms and Conditions

Figure 4 Survival in patients with DAH and IAH. Shown are Kaplan-Meier survival curves depicting outcomes in the first 180 days after onset of the initial episode of AH in patients with DAH (A) and patients with IAH (B). The solid line represents the rFVIIa group; the dashed line, the conventional therapy group. Biology of Blood and Marrow Transplantation 2014 20, 969-978DOI: (10.1016/j.bbmt.2014.03.015) Copyright © 2014 Terms and Conditions

Figure 5 Autopsy sections of representative lung histopathology. (A) Hematoxylin and eosin staining showing accumulation of red blood cells, fibrin, and hemosiderin-laden macrophages in alveolar spaces. (Original magnification, 20×.) (B) Iron staining highlighting hemosiderin-laden macrophages within the alveolar and interstitial spaces. (Original magnification, 20×.) (C and D) C4d staining highlighting predominantly large-caliber vessels (C) and hyaline membranes (D). (Original magnification, 20×.) Biology of Blood and Marrow Transplantation 2014 20, 969-978DOI: (10.1016/j.bbmt.2014.03.015) Copyright © 2014 Terms and Conditions

Figure S1 Biology of Blood and Marrow Transplantation 2014 20, 969-978DOI: (10.1016/j.bbmt.2014.03.015) Copyright © 2014 Terms and Conditions

Figure S2 Biology of Blood and Marrow Transplantation 2014 20, 969-978DOI: (10.1016/j.bbmt.2014.03.015) Copyright © 2014 Terms and Conditions

Figure S3 Biology of Blood and Marrow Transplantation 2014 20, 969-978DOI: (10.1016/j.bbmt.2014.03.015) Copyright © 2014 Terms and Conditions

Figure S4 Biology of Blood and Marrow Transplantation 2014 20, 969-978DOI: (10.1016/j.bbmt.2014.03.015) Copyright © 2014 Terms and Conditions

Figure S5 Biology of Blood and Marrow Transplantation 2014 20, 969-978DOI: (10.1016/j.bbmt.2014.03.015) Copyright © 2014 Terms and Conditions

Figure S6 Biology of Blood and Marrow Transplantation 2014 20, 969-978DOI: (10.1016/j.bbmt.2014.03.015) Copyright © 2014 Terms and Conditions